For a full breakdown of how BPC-157 fits into the Wolverine Stack and what patients can expect from the combination, see our complete Wolverine Stack guide
Levine T, Muley S
In its lawsuit, the OFA said that the FDAs decision to end the shortage was a reckless and arbitrary move and could deprive patients of a vital treatment for type 2 diabetes and obesity. In an interview with BioSpace last month, David Rosen, partner at Foley & Lardner, said that the lawsuit is a precedent in this area. Prior to the OFA suit, no one has ever challenged the FDAs decision to remove a therapy from the drug shortage list. The OFA case is still ongoing, with the next court update due on Thursday
Conference proceedings were searched including the EASD, the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), the International Diabetes Federation and the ADA Scientific Sessions
Extremely happy with the results
Many people like this system because it avoids confusion